9-MBC (9-Methyl-beta-carboline)
Heterocyclic beta-carboline derivative with putative dopaminergic regenerative properties. In vitro and rodent studies suggest upregulation of tyrosine hydroxylase, enhanced dendrite outgrowth in dopaminergic neurons, and anti-inflammatory effects on microglial cells via inhibition of NF-kB. Hypothesized to promote regeneration of dopaminergic neurons in the substantia nigra. Zero completed human clinical trials. Photosensitizing properties are a known safety concern.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- alt
- ast
- ggt
- prolactin
- photosensitivity-disorders
- concurrent-uv-exposure
- pregnancy
- lactation
- parkinsons-medication-concurrent
- PMID:227186719-Methyl-beta-carboline exerts neuroprotective effects and induces neurite outgrowth in dopaminergic neurons — Neurotoxicol Teratol, 2012
- PMID:20957497Beta-carbolines as regulators of neuroplasticity and neurogenesis — Curr Top Med Chem, 2010
- PMID:16411200Neurotrophic and neuroprotective actions of beta-carbolines — Ann N Y Acad Sci, 2005
9-MBC is the compound this tool must include and simultaneously cannot endorse. Zero human trials. Zero human pharmacokinetic data. The rodent data on dopaminergic neurite outgrowth is genuinely interesting. But photosensitization is a real mechanism — beta-carbolines form DNA adducts under UV exposure. The self-experimenter community treats this as a dopamine recovery tool, typically post-stimulant abuse. The risk profile is uncharacterized by definition. Tier 3 means exactly what it says. This is a research compound. Treat it as one.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See 9-MBC (9-Methyl-beta-carboline) in a protocol matched to you